Clinical Trial Update: Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors [NA]

View source ↗

Summary

Clinical trial update on theranostics using radiolabeled somatostatin antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in neuroendocrine tumors completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 177Lu-DOTA-JR11 (unknown)
• 68Ga-DOTA-JR11 (unknown)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroendocrine Tumors | NA | Status: COMPLETED | Results posted: 2022-02-01